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ABSTRACT
The development of specific antiviral therapy has increased the
need for rapid viral diagnosis and necessitates a better understanding
of viral epidemiology.

The purposes of this study were to determine the

efficiency of immunofluorescent assay employing monoclonal antibodies
from commercial sources to detect respiratory virus antigens in clinical
specimens and to define the epidemiology of respiratory viruses in
Bismarck, North Dakota.
Throat swab, nasopharyngeal swabs and nasopharyngeal washes
were excellent specimens for studying viral epidemiology; virus
isolation rates were 7.7%, 33.2%, and 39.7%, respectively.
epidemics of respiratory syncytial virus
observed.

Yearly

and influenza were

In contrast, parainfluenza and adenovirus infections

occurred endemically throughout the study period.

Children less than

6 years of age and adults greater than 50 years of age had the highest
viral morbidity.

Respiratory syncytial and influenza were the most

frequently isolated viruses.
Nasopharyngeal swab and nasopharyngeal wash specimens were
evaluated for the ability to harvest ciliated epithelial cells from
the upper respiratory tract.

Overall, 8.7% of the specimens were

unsuitable for immunofluorescent assay.

The probability of specimen

rejection was source- and patient age-dependent.

The rejection rate

for NPW specimens was more than twice that for NPS specimens and the
xi

rejection rate for specimens from patients greater than 7 years of age
was approximately 5 times higher than the rate for specimens obtained
from patients less than 6 years of age.
Immunofluorescent assay was a sensitive and specific method for
rapid diagnosis of respiratory viral infections in cell cultures.

The

Bartels indirect fluorescent antibody reagents exhibited acceptable
levels of sensitivity (overall 84.6%, range 33.3 - 100%) and specificity
(overall 83.3%, range 87.3 - 100%).

The Whittaker direct fluorescent

antibody reagents had poor sensitivity (overall 50%, range 18.2 - 94.1%)
and high specificity (overall 91.5%, range 93.8 - 100%).

The highly

efficient Bartels reagents for respiratory syncytial virus and influenza
A virus could be used as acceptable alternatives to culture for these
viruses.

The specificity of the influenza B, parainfluenza 3 and

adenovirus reagents allowed for rapid presumptive diagnosis but were not
sufficiently sensitive to replace culture.
Shell vial assays using HEp-2 and A549 cells offered no diagnostic
advantage over immunofluorescent assay or conventional tube cell culture
for the identification of respiratory viruses.
Immunofluorescent assay using commercial monoclonal antibodies was
a sensitive and specific method for rapid diagnosis of respiratory virus
infections and has the potential to replace expensive and laborious
conventional culture methods.
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INTRODUCTION

Etiology of Respiratory Illness
Respiratory infections are a major cause of morbidity in humans;
more than 25% of all visits to or by physicians are motivated by
symptoms of respiratory illness (1).

Viruses, bacteria, rickettsiae,

and fungi cause respiratory infections and diseases.

The etiology of

respiratory disease can vary from season to season, from year to year,
and especially from one age group of patients to another (2).
Infectious particles may be implanted directly on nasal surfaces from
contaminated hands, from large respiratory droplets or from finely
dispersed, aerosolized respiratory secretions which may reach the lower
respiratory passages (2).

Since humans continually breathe the

environmental air about 20 times a minute and are in direct or indirect
daily contact, it is no wonder that exposure to and infection with
respiratory agents is common.
Of all microbial agents, respiratory viruses are probably the most
common cause of symptomatic and possible asymptomatic infections.

It is

estimated that the common cold accounts for more than half of all
absences from work and one quarter of the total time lost by industrial
employees in the United States (1).

In children and young adults, over

90% of respiratory infections are viral (3,4).

Older children and

adults are more likely to have less severe symptoms but are an important
source of viruses for infants and the elderly (2).
1

In infants under 2

2

years of age, respiratory syncytial virus and parainfluenza virus types
1 and 3 are the most important viral respiratory pathogens.

Influenza

is of morbidity importance in all age groups, but the mortality is
highest with infections in infancy and in the aged.

As advances in

antiviral chemotherapy are made, concurrent advances in rapid diagnosis
are needed.

Current antiviral agents are virus specific and patients

will benefit most by earlier diagnosis and treatment.

Specific and

rapid laboratory diagnostic procedures are needed for the optimal
management of respiratory diseases.
Viral respiratory infections may be inapparent or symptomatic
ranging from mild, self limiting diseases such as the common cold to
severe and even fatal pneumonias (1).

Viral respiratory disease is more

common in the very young and elderly populations than in other age
groups (2).

These infections can be broadly categorized into several

viral respiratory syndromes including diseases of the upper respiratory
tract; the common cold, acute febrile pharyngitis, pharyngoconjunctival
fever, acute respiratory disease, herpangina, and diseases of the
lower respiratory tract including bronchitis, bronchiolitis and
pneumonia, and an influenza-like syndrome.

Viral infections that are

confined to the respiratory tract can be caused by members of a least 5
major virus groups:

Orthomyxoviridiae (influenza viruses),

Paramyxoviridae (parainfluenza viruses and respiratory syncytial virus),
Picornaviridae (enteroviruses and rhinovirus), Coronaviridae
(coronavirus) and Adenoviridae (adenovirus) (1).
Most respiratory viruses produce illness through the direct
consequences of local multiplication.

Necrosis and lysis occur with

3

desquamation of the respiratory epithelium (2).

Constitutional symptoms

result from breakdown products of dying cells that are absorbed into the
bloodstream.

Fever is produced by the liberation of endogenous pyrogens

such as interleukin 1 resulting from the anti-viral action of
macrophages.

Myalgia, which may be severe in respiratory infections

such as influenza, results from interleukin 1-induced release of
prostaglandin E2 and enhanced catabolism in muscle cells (5).

The more

desirable results of viral induced immune mechanisms are eradication of
infection and immunity.
Usually the maintenance of low levels of secretory antibody or of
cell-mediated immune sensitization provides a protective barrier to
virus infection in the respiratory tract (6).

The development of T

cells with cytotoxic activity specific for virus-infected cells appears
to be a critical factor in restricting virus infection to the
respiratory tract and eradicating the infection (6).

Resistance to

local reinfection has generally been attributed to the presence of
sufficient antibody in serum or in respiratory secretions.

From the

nasopharynx to the bronchiolar level, the principal antibody isotype
appears to be IgA and in the lower respiratory tract, IgG antibody
becomes progressively more predominant (6).
Virus-specific immune mechanisms may contribute directly to the
pathogenesis of a virus infection.

If humoral antibody is present in

the absence of local antibody, then a more severe reaction may occur
(2,6).

The mechanism for this is not clear but the phenomenon has been

observed in infants with actively and passively acquired respiratory
syncytial virus (RSV) immunity who subsequently develop a reinfection

4

with this virus.

One possibility is that IgG4 and IgE, as

'

homocytotrophic antibodies, may exacerbate the symptoms of respiratory
infection (6).

There is evidence that the cytotoxic T-cell response to

influenza virus infection may also contribute to the pathogenesis of
disease.

Immunocompetent mice had enhanced pulmonary pathology and

shorter survival than nude mice following infection with influenza virus
(7).

Cell-mediated immune hyperresponsiveness has been implicated as a

risk factor in the development of lower respiratory disease with RSV
infection.

Recipients of an inactivated RSV vaccine developed

exaggerated cell-mediated immune responses following vaccination and
experienced more severe forms of illness with natural-acquired infection
than an unvaccinated control group (8).
The influenza viruses are enveloped, negative-strand RNA viruses
containing a genome of 8 linear segments (9).

Two virus-coded

glycoprotein antigens are found in the surface envelope; hemagglutinin
(HA) and neuraminidase (NA) (10).

Cellular infection is initiated by

the attachment of the hemagglutinin molecules to host cell membrane
glycoproteins containing sialic acid.

The hemagglutinin is a trimeric

molecule that projects from the viral membrane and is composed of a
fibrous stem region that supports three globular domains (11).

The

receptor binding domain of the hemagglutinin is a pocket of highly
conserved amino acids located near the top of each of the three globular
domains.

Neuraminidase facilitates release of newly formed virus

particles from infected cells.

The surface glycoproteins of newly

synthesized virions contain N-acetylneuraminic acid (NANA) as part of
their carbohydrate structure.

A major function of NA is the enzymatic
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removal of the NANA residues to disrupt or prevent the occurrence of
aggregates and thereby increase the number of free infectious particles.
Both surface proteins are antigenic and antibodies to them are involved
in development of acquired immunity (10).

The nucleoprotein and matrix

antigens of the influenza viruses are antigenically type-specific and
stable and enable immune typing of the viruses into types A, B, and C
(

12 ).
Point mutations and gene reassortment among viruses of the same

type, which occur in the gene segments coding for HA and NA proteins,
accounts for antigenic drift and shifts (9).

Such antigenic variation,

particularly among type A viruses, results in the periodic epidemics and
pandemics of influenza (13).
seasonality.

Influenza infections have marked

In temperate climates, epidemics occur almost exclusively

in winter months (3).

Infection with influenza virus may be

asymptomatic, may cause only a slight fever, or may result in the
prostrating illness that occurs during epidemics of influenza (3,13).
In a lengthy, prospective study of respiratory virus infections in
infants and young children in a Washington, D.C. pediatric practice,
influenza viruses ranked 4th in importance after RSV, the parainfluenza
viruses and the adenovirus group as a cause of respiratory disease
severe enough to require medical attention (13).

In a 6 year study of

acute respiratory illness in a small Michigan community, the influenza
virus group accounted for 11.9% of all viruses isolated and was the
third most frequent cause of illness (3).

The major site of infection

for influenza viruses is the ciliated columnar epithelial cell (14,15).
Nasal and tracheal ciliated cells are extensively necrotized as early as
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the first day after the onset of symptoms.

Local inflammation follows

and repair of the epithelium begins between the third and fifth day.
After 15 days, cilia and mucus production reappear (14).

Recovery from

uncomplicated influenza begins 3 to 4 days after onset, although
complaints of weakness, fatigue, and cough may persist for 1 week or
longer.

Pneumonia of viral or secondary bacterial origin is an

important complication particularly in the elderly or in patients of any
age with chronic debilitating illness (1).

Amantadine hydrochloride

provides prophylactic benefit in adults and children, however, this
antiviral agent lacks activity against influenza B virus.

Ribavirin has

been used successfully in the treatment of both influenza A and B in
adult populations (16).

Yearly vaccinations of high risk groups with a

continually updated, trivalent, inactivated vaccine is the primary
prophylactic measure for influenza disease.
The genome of the parainfluenza viruses consists of a singlestranded, negative polarity RNA in unsegmented, linear form (17).
surface glycoprotein spikes project from a viral envelope:

Two

a

hemagglutinin-neuraminidase (HN) protein complex and a fusion (F)
protein (17).

The HN protein is the reactive site which binds to the

cell receptors and the F protein mediates the infectivity of the virus
(17).

Type specific antigens in the nucleocapsid allow for

differentiation into 4 distinct serotypes (18).

Unlike the influenza

viruses, the parainfluenza viruses are genetically stable.
The parainfluenza viruses are ubiquitous agents and among the more
important viral respiratory pathogens of humans.

They cause upper

respiratory tract infections at all ages and are frequent causes of
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acute lower respiratory tract disease in infants and young children'
(3,19).

In an 11 year study of croup in a pediatric practice, the

parainfluenza viruses constituted 74% of the agents isolated (20).
major isolate was parainfluenza virus type 1.

The

Type 2 virus produced

similar illness to type 1 but with much less frequency.

In a 6 year

study of parainfluenza virus type 3 infections in a Houston pediatrics
practice, type 3 closely mimicked RSV in clinical manifestations in
infants less than 1 year of age and was second only to RSV as a cause of
pneumonia and bronchiolitis in infants (21).

Type 3 infections occurred

in epidemics with activity peaking in the spring.

Virtually all

children in the study were infected with parainfluenza virus type 3 by
age 3.

Parainfluenza viruses caused 16.9% of all respiratory illnesses

and were second only to rhinoviruses as a cause of respiratory illness
in a 6 year study of acute respiratory illness in Tecumseh, Michigan
(3).

Generally, most primary parainfluenza virus infections are

symptomatic with a high proportion affecting the lower respiratory tract
(21).

Of the primary infections that involve the upper respiratory

tract, most are accompanied by fever and laryngitis or tracheitis (21).
Inoculation with the parainfluenza viruses occurs via the upper
respiratory tract with infection of the nasal epithelium and the
nasopharynx (22).

With primary infection, inflammation may be present

throughout the respiratory tract in young children.

Although the

subglottic tissues may appear particularly involved, inflammation occurs
in the conducting airways at all levels including the alveoli (22).
Necrosis of the respiratory epithelium is a prominent feature in the
infection process (22).

8

Respiratory syncytial virus, a Paramyxovirus, has envelope
glycoproteins but lacks hemagglutinin and neuraminidase activity (23).
Two smaller glycoproteins (FI and F2), similar to the fusion protein of
parainfluenza viruses, relate to infectivity of the virus (17,23).
Group specific antigens are present in both the envelope and
nucleocapsid (24).
Respiratory syncytial virus is the most important pathogen in
infancy and early childhood and is the only viral agent that produces
its most severe disease in the first several months of life when
specific maternal antibody is uniformly present in the infant's serum
(24,25,26).

This viral respiratory pathogen causes sizable outbreaks of

infection each year and circulates so efficiently that virtually all
children in their first year of life are infected (24,25,27).
Infections in children involve principally the lower respiratory tract.
In a study of 13 consecutive respiratory seasons in Washington, D.C.,
each RSV epidemic lasted approximately 5 months with a peak incidence
closely associated with a dramatic increase in the number of infants and
young children who were hospitalized with lower respiratory tract
disease, especially bronchiolitis and pneumonia (27).

Infection with

RSV occurred in 43% of inpatients with bronchiolitis, 25% of patients
with pneumonia and 23% of all inpatients with acute respiratory tract
disease.

Respiratory syncytial virus caused 5.9% of acute respiratory

illness in a small American community (3).

Respiratory syncytial virus

does not respect age, continuing to cause symptomatic infections
throughout life (28).

Viral infection in older children and adults may

be the source for continued spread of RSV infection in a community (28).
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Inoculation of RSV is through the upper respiratory tract with'
infection occurring in the respiratory epithelium (29).

From the upper

respiratory tract the virus may spread to the lower respiratory tract to
involve the conducting airways at all levels (30).

The main lesion in

acute bronchiolitis is epithelial necrosis with a dense plug forming in
the bronchiolar lumen leading to trapping and other mechanical
interference with ventilation.

These pathologic changes adversely

affect the mechanics of the infant's respiration by causing a markedly
increased lung volume and higher expiratory resistance.

In RSV

pneumonia, the characteristic finding is an interstitial infiltration
of mononuclear cells (31).

The lung parenchyma are edematous with areas

of necrosis, leading to alveolar filling, consolidation, and collapse.
The severity of symptoms following RSV infection is not due to a
deficient cellular response, but rather to cell-mediated
hyperresponsiveness (6).
Adenoviruses are non-enveloped, double-stranded DNA-containing
viruses (32).
symmetry.

The capsid contains 252 capsomeres and has icosahedral

The capsomeres consist of 240 hexons and 12 pentons with a

projecting fiber on each penton.

Hexons are group-specific antigens and

induce neutralizing antibodies; the fibers are largely responsible for
type-specific antibody induction.

The pentons have mixed functions and

are especially active in hemagglutination (33).

A monoclonal antibody

has been produced and characterized that reacts with a common hexon
epitope of all 41 adenovirus serotypes (34).

Adenoviral infections

accounted for 2 to 5% of total respiratory illness in a study in
Seattle, Washington (35), and adenoviruses were isolated from 4.5% of
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patients exhibiting acute respiratory illness in a Tecumseh, Michigan
study (3).

In a 10 year study of pediatric respiratory disease in

Washington, D.C., adenoviruses accounted for approximately 7% of these
diseases with a clinical distribution in these percentages:

12.4% of

mild upper respiratory tract infection, 10.4% of pharyngitis, 6.3% of
croup, 10.6% of bronchiolitis and 11.6% of pneumonia (26).
In most instances, initial adenovirus infection occurs in the
respiratory tract and involves the mucus membranes of the nose,
oropharynx and conjunctiva (36).

In tracheal organ cultures, the growth

of adenovirus 7 was characterized by an initial focal cytopathology
that quickly progressed to involve the whole epithelium (37).
Frequently the cilia of inclusion-bearing cells were found to be intact.
Picornaviruses are small, nonenveloped viruses with a genome
consisting of a linear, single-stranded, positive-sense RNA molecule
(38).

The family Picornaviridae includes 2 genera of human pathogens:

rhinoviruses and enteroviruses.

The enteroviruses (polioviruses,

echoviruses, coxsackie A and B viruses, enterovirus serotypes 68,69,70,
and 71, and hepatitis A virus) are found mainly in the gastrointestinal
tract and are stable at pH 3.0; the rhinoviruses are found primarily in
the nose and are inactivated at pH 3.0 (38).

The protein coat of the

picornaviruses forms an icosahedral shell consisting of sixty protomers
arranged in twelve pentameric units.

Each protomer contains one copy of

each of the viral proteins VP1, VP2, VP3, and VP4.

In both poliovirus

and rhinovirus capsids there is a deep depression surrounding the vertex
of each of the pentameric units.

These depressions have been proposed

to be sites that bind to the host receptor.

The receptor site on the
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host cell for rhinovirus and poliovirus is a member of the
immunoglobulin superfamily (11).
Although more than 100 serotypes constitute the genus Rhinovirus,
no common antigen is found in all serotypes (39).

Rhinoviruses are

associated primarily with mild upper respiratory tract disease (the
common cold) and are believed to cause 30 to 50% of all acute
respiratory illness (40,41).
Rhinovirus infection occurs via the respiratory route and, despite
the marked local response to infection, little destruction of the nasal
mucosal epithelium is noted (42).

Only a few rhinovirus-containing

ciliated epithelial cells were shed from the nasal membranes of
laboratory-infected volunteers (43).

In this study, the acute stage of

rhinitis was characterized by edema of the mucus membrane with exudation
of serous and mucinous fluid, i.e. the common cold.
Although there are some minor cross reactions between several
coxsackievirus and echovirus groups, there are no common group antigens
of diagnostic importance (44).

Coxsackievirus A21 is the only

enterovirus that clearly qualifies as a common cold virus, producing
epidemics of mild respiratory illness in military populations (45).
Pharyngitis is a common clinical manifestation of coxsackie and
echoviral infections (45).

Probably all enteroviruses on occasion cause

mild pharyngitis which is usually abrupt in onset, without prodrome and
accompanied by fever (45).

Croup, bronchitis, bronchiolitis and

pneumonia have been sporadically associated with coxsackievirus and
echoviruses (45).

Epidemic myalgia (pleurodynia or Bornholm disease) is

characterized by a sudden onset of fever and chest pain which likely
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results from viral infection of muscle cells (46).

The major etiologic

agents in epidemic myalgia are coxsackieviruses B3 and B5 (46).
Herpangina, with symptoms of fever, pharyngitis, dysphagia, abdominal
pain, and vomiting is caused by coxsackie A viruses in young children
(45).

Enteroviruses contribute significantly to the burden of disease

in a community; 4.3% of the respiratory illnesses observed during a 6
year study in Tecumseh, Michigan were caused by enteroviruses (3).
Transmission of enteroviruses is from person to person by fecaloral and possibly oral-oral routes (45).

Following initial acquisition

of virus, implantation occurs in the pharynx and the lower alimentary
tract (45).

The pathologic findings in patients with mild respiratory

tract infections have not been described.
Human coronaviruses are enveloped, single-stranded, positive-sense
RNA viruses with club-shaped surface projections that give the
appearance of a solar corona (47).

Because of the fastidious growth

requirements of coronaviruses, successful isolation of most serotypes is
dependent upon the utilization of organ cultures of human ciliated
respiratory epithelial tissues (48).

Coronaviruses are the second most

important viral group responsible for the common cold and infection is
clinically manifested by a general malaise, headache, rhinorrhea, and a
sore throat (49).
Coronavirus infection begins in the upper respiratory tract,
destroying the ciliated epithelium of the trachea and nasal mucosa (50).
Infections are characterized by sharp midwinter outbreaks between
December and April (49).
The rapid diagnosis of RSV, influenza A and B virus, parainfluenza
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virus types 1, 2, and 3, and adenovirus infections has received a great
deal of attention because of the severe disease associated with these
agents.

Fortunately, these viruses exhibit group specific antigens and

rapid immunologic identification can be made.

The impetus to develop

rapid diagnostic techniques for the enteroviruses, rhinoviruses and
coronaviruses has been blunted by the fact that these viruses lack group
specific antigens.

Enteroviruses, rhinoviruses and coronaviruses are

generally of little concern in the laboratory because of an absence of
immunologic methods for group specific identification, fastidious
culture requirements, and a general association with mild upper
respiratory tract symptoms.

Diagnosis of Respiratory Virus Infections

Serology and isolation in cell culture are the traditional methods
for the laboratory diagnosis of viral respiratory illnesses.

Although

these time-honored tests remain the "gold standard" against which new
methodologies are compared, they are inherently slow; acute- and
convalescent-phase sera must be separated by at least 7 days, and the
median time for detection of all viruses in cell culture is 4 days (51).
With the advent of specific antiviral therapy, more rapid methods of
viral diagnosis are highly desirable.
Circulating antiviral antibodies, particularly neutralizing
antibodies, are widely accepted as evidence of recent or past infection
with a particular virus.

Demonstration of a fourfold increase in

specific antiviral antibody is considered diagnostic of a recent
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infection.

Serology has the advantage of establishing a diagnosis when

virus isolation either is negative or cannot be attempted.

A negative

viral serologic test can often exclude a specific virus from etiologic
possibilities, whereas failure to isolate the virus or to detect
specific viral antigens in patients specimens cannot.

On the other

hand, all serologic diagnoses must be considered presumptive to some
degree because serologic cross reactions within many virus groups occur.
The delay in diagnosis obviates conventional serologic methods as useful
for guiding decisions concerning prompt initiation of specific antiviral
chemotherapy.
Methods that identify viruses in cell culture before observation of
cytopathic effect have been studied as a way to decrease time for
detection of viruses.

Hemadsorption, which detects influenza A,

influenza B and parainfluenza type 1, 2, and 3 viral hemagglutinin in
primary monkey kidney cells, showed that 38% of all viruses could be
detected by 24 hours, 69% could be detected by 48 hours and 96% could be
detected by 5 days (52).

The poorest recovery was for parainfluenza

type 2 virus; 82% detection at 5 days.

All viruses were detected by day

10 .
Immunologic techniques such as enzyme-linked immunosorbent assay
(ELISA) and immunofluorescence microscopy (IFM) have been used to detect
respiratory virus antigens in clinical specimens with results available
in a matter of hours.
Most ELISAs that detect respiratory virus antigens employ a capture
antibody bound to a solid phase (53).

Incubation with a clinical

specimen results in binding of viral antigen to the bound antibody.

The
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captured viral antigen is then detected by another specific antibody
which is conjugated to an enzyme.

The bound enzyme is detected and

quantitated by the development of color when an appropriate substrate is
added.

These assays have objective endpoints and can be performed with

automated instrumentation, making them ideal for testing large numbers
of samples.

Assays have been constructed using monoclonal or polyclonal

antibodies.
Immunofluorescence microscopy (IFM) is the most commonly practiced
rapid technique in diagnostic laboratories today (54).

The introduction

of monoclonal antibodies (MAB) has improved the reliability and
broadened the acceptance of IFM as a rapid viral diagnostic tool.

Many

of the MABs used in IFM are commercially available, permitting the wide
dissemination of standardized reagents that have greater specificity and
much lower background fluorescence than polyclonal sera (54).

Because

the endpoint is subjectively determined, diagnosis by IFM requires
experience and careful interpretation.
Although rapid, the usefulness of immunologic tests in clinical
practice must be determined.

A predictive value model of diagnosis

describes the explicit relationship between test results and the state
of health (55).

A true negative (TN) result occurs when a test is

negative and the patient's state of health is normal.

Conversely, when

the test is positive and the patient has disease, the patient is
correctly identified as having the disease.
positive (TP) result.

This constitutes a true

Since uncertainty accompanies even the best

clinical tests, false positive (FP) and false negative (FN) test results
can occur.

Patients without disease but demonstrating a positive test
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result are categorized as being FP and patients with disease and
demonstrating a negative test are categorized as FN.

The predictive

value model can be used in diagnostic medicine to evaluate whether a
positive or a negative result is correct (Table 1).

The predictive

value of a positive test result is the percentage of TP results with
respect to all individuals with positive test results.

Similarly, the

predictive value of a negative test result is the percentage of TN test
results in all individuals who have negative test results.
Two additional parameters, sensitivity and specificity can be
calculated (Table 1) and are assumed intrinsic properties of the test.
A test's sensitivity is the percentage of known diseased subjects with
positive test results among all the diseased subjects tested.

The

specificity of a test is the percentage of subjects with negative
results among all known nondiseased subjects tested.
An important factor affecting the usefulness of a test result is
prevalence which is defined as the percentage of the population that
exhibits the disease at a point in time divided by the total (both
diseased and nondiseased) population.

The predictive value model can be

expressed algebraically as a function of disease prevalence and the
sensitivity and specificity of a diagnostic test (Table 2) (55).

As the

prevalence of a disease increases in the tested population, the
predictive value of a positive test result increases.

Conversely, as

the prevalence of disease in the test population increases, the
predictive value of a negative test result decreases because of the
proportionately greater number of false negative test results.
A fluorescent focus chamber slide assay utilizing murine monoclonal
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Table 1.

Predictive value model showing the relationship between test
results and state of health (55).

Category of
Positive
Result

Category of
Negative
Result

Diseased
(Culture
Positive)

TP

FN

Nondiseased
(Culture
Negative)

FP

TN

Group

TP - True Positive
FN - False Negative
FP - False Positive
TN - True Negative
Sensitivity = TP/(TP + FN)
Specificity = TN/(TN + FP)
Predictive Value Positive = TP/(TP + FP)
Predictive Value Negative = TN/(TN + FN)
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Table 2.

Predictive value model expressed algebraically (55).

Group

Positive Result

Negative Result

Diseased

(prev)(sens)

(prev)(l - sens)

Nondiseased

(1 - prev)(l - spec)

(1 - prevHspec)

Prevalence (prev) = (TP + FN)/(TP + FN + TN + FP)
Sensitivity (sens) = TP/(TP + FN)
Specificity (spec) = TN/(TN + FP)
Predictive Value Positive = [(prev)(sens)]/[(prev)(sens) + (1 - prev)
(1 - spec)]
Predictive Value Negative = [(1 - prev)(spec)]/[(prev)(1 - sens)] +
[(1 - prev)(spec)]
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antibodies directed against conserved epitopes of influenza A and Bviruses was compared to virus isolation using Madin-Darby canine kidney
cells (MDCK) (56).

Clinical specimens were inoculated onto MDCK

monolayers in chamber slides, incubated for 24 hours and stained with
monoclonal antibody.

Compared with immunofluorescent staining of

conventional cell culture monolayers, 24 hour cell culture chamber
slides had a sensitivity of 75% and a specificity of 95%.

A

retrospective study evaluating the efficacy of influenza type A- and Bspecific monoclonal antibodies in an indirect immunoperoxidase (IPA)
staining procedure was performed on primary monkey kidney cell
monolayers 24 hours postinoculation with stored clinical specimens (57).
The IPA stain detected influenza virus is 86% of stored clinical
specimens from which the virus was reisolated.

An enzyme immunoassay

(ElA) employing the same monoclonal antibodies as described in the IPA
procedure was used to detect influenza viruses reisolated from clinical
specimens in tissue culture (45).

At 48 hours postinoculation, 64% of

H1N1 and 94% of H3N2 influenza A specimens and 79% of influenza B
specimens were detected.
Enzyme-linked immunosorbent assay (ELISA) is a highly specific
method of determining the presence of RSV antigen is nasopharyngeal
secretions (58-63).

Sensitivities of this assay when compared to cell

culture have ranged from 61 to 94%.

Although immunofluorescence appears

to be slightly more sensitive than ELISA for the detection of RSV in
clinical specimens, ELISAs require no special equipment and only minimal
training (63).
Detection of influenza A virus in nasal wash specimens by one ELISA
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was not sufficiently sensitive nor specific for routine laboratorydiagnosis of influenza (64).

Only 10 of 20 culturally-proven infections

were positive in the test and 2 of 13 patients with rhinovirus
infections were falsely positive.

Using another ELISA procedure, Harmon

and Pawlik were able to detect influenza A and adenovirus antigens in
nasal wash and throat swab specimens with only a 62% and 53% efficiency,
respectively (65).

Neither of these ELISA tests are commercially

available.
August and Warford evaluated a commercial ELISA test for the
detection of adenovirus in conjunctival, respiratory and fecal specimens
(66).

Of 45 culture positive specimens, 25 (56.8%) were positive by

ELISA.

Wiley and colleagues demonstrated an overall sensitivity and

specificity of 69% and 100%, respectively, for detection of adenovirus
from ocular specimens (67).

Despite the low sensitivity of this ELISA

test, advantages of the test include the ability to detect the
noncultivable adenovirus 40 and 41, and the potential for automation.
Centrifugation of clinical specimens onto monolayers in shell vials
(shell vial assay) is thought to enhance the infectivity of viruses.
Rapid techniques for the detection of cytomegalovirus and herpes simplex
virus in shell vial cultures 16 hours postinoculation using monoclonal
antibodies with an indirect fluorescent antibody (IFA) procedure have
yielded results superior to those obtained with conventional tube cell
cultures (68,69).
Several studies applying the shell vial assay for the detection of
respiratory viruses have been undertaken.

Epsy and colleagues detected

only 56% of influenza strains by IFA in the shell viral assay (SVA) 24
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hours postinoculation as compared to conventional primary monkey kidney
tube cell cultures (70).
increased slightly to 60%.

At 48 hours postinoculation, the sensitivity
The SVA was never positive in the absence of

the isolation of influenza virus in conventional tube cell cultures.
Using the same antibodies, Stokes and colleagues demonstrated an 84%
sensitivity and 100% specificity with a MDCK-seeded SVA.

A monoclonal

antibody specific for the adenovirus group-reactive hexon antigen was
used for the detection of adenoviruses by IFA 24 and 48 hours
postinoculation of HEp-2 monolayers in shell vials (71).

Of 31

adenovirus isolates, 16 (52%) and 30 (97%) were detected after
incubation for 24 hours and 48 hours, respectively.

August and Warford,

using a commercial monoclonal antibody with a 72 hour SVA, were able to
demonstrate an 86% sensitivity and 100% specificity compared to human
foreskin fibroblast tube cell cultures (66).
Efficient immunologic detection of respiratory virus antigen in
direct clinical specimens is dependent upon 2 factors:

the availability

of reliable antisera and collection procedures that result in specimens
containing detectable amounts of viral antigen.
Suitable monoclonal antibodies would be an obvious advantage over
polyclonal sera for laboratory diagnosis.

They would provide long-term

reagent consistency and could be used without adsorption to remove cross
reacting tissue-specific antibodies.

In a study comparing polyclonal

antiserum to monoclonal antibodies for the rapid detection of influenza
A virus in respiratory specimens by immunofluorescence, monoclonal
antibodies were more sensitive and accurate than polyclonal antiserum,
and the monoclonal preparation was easier to interpret (72).
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Infection with respiratory viruses occurs via the respiratory '
epithelium and viral antigen can be demonstrated in sloughed columnar
epithelium (14,30,37,43).

Nasal wash specimens are superior to either

throat swabs or nasopharyngeal swabs for RSV isolation (73).

An

aspiration method utilizing a portable suction catheter and secretion
trap for collection of nasopharyngeal secretions was used successfully
to collect specimens for direct antigen detection and culture (74).

An

effective and simple method for collection of nasal wash specimens that
does not require a suction apparatus was described by Hall (75).
Specimens obtained by this method contained titers of RSV that were on
average 500-fold higher than those obtained by using a conventional
nasopharyngeal swab method.

Alternatively, nasopharyngeal swab

specimens compared favorably with nasopharyngeal suction-collected
specimens with respect to the number of specimens suitable for
immunofluorescence (76).

For the detection of virus antigens in direct

clinical specimens by immunofluorescence, satisfactory specimens should
contain at least 1 ciliated epithelial cell per 400X field (76,77).
The use of immunofluorescence for the rapid detection of
respiratory viruses in cells shed from the nasopharynx during infection
is a sensitive diagnostic procedure (77).

A more widespread use of

immunofluorescence has been limited by a shortage of antisera of
acceptable quality (78).

Table 3 summarizes the efficiency of

immunofluorescence for detection of respiratory viruses from clinical
specimens.

These data suggest the immunofluorescence could be used as

an alternative to culture for RSV (63).

The specificity for the

remaining viruses appears sufficiently great to allow a confident
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Table 3.

Efficiency of immunofluorescence for detection of respiratory
viruses in clinical specimens.
Antibody
Type/Source

Virus
Influenza A

Sensitivity

Specificity Reference

P(1 )/C(2)
P/C
P/C
M(5)/PR(6)
P/C
M/PR

IFA(3)
DFA(4)
DFA
IFA
IFA
IFA

43
88
73
38
46
69

100
88
90
91
75
86

79
76
74
56
72
72

P/C
P/C

DFA
IFA

71
63

99
98

76
79

Type 2

P/C

DFA

76

100

76

Type 3

P/C
P/C

DFA
IFA

69
31

99
100

76
79

P/C
P/C
P/PR

DFA
IFA
IFA

100*
28
62

99
100
-(7)

76
79
80

P/C
P/C
P/C
P/C
P/PR
P/C
M/PR
M/PR

DFA
IFA
IFA
DFA
IFA
DFA
IFA
IFA

92
93
95
95
92
94
95
97

95
94
96
91
94
69
87
89

76
79
81
82
83
84
85
86

Parainfluenza
Type 1

Adenovirus

Respiratory
syncytial

(1)
(2)
(3)
(4)
(5)
(6)
*
(7)

Method

-

Polyclonal
Commercial
Indirect Fluorescent Antibody
Direct Fluorescent Antibody
Monoclonal
Private
Low Numbers
Undetermined
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presumptive diagnosis.
to be improved.

The sensitivity for viruses other than RSV needs

It is suggested that immunofluorescence be an adjunct

to, and not a replacement of, appropriate cell culture isolation systems
(79).
Rapid diagnostic procedures are not available for coronaviruses,
rhinoviruses and enteroviruses.

Coronaviruses generally require

tracheal organ culture for hi vitro isolation and commercially produced
antibodies are not available for detection of this virus by
immunofluorescence or ELISA.

Rhinoviruses and enteroviruses lack a

common antigen, therefore immunofluorescence and ELISA procedures have
not been developed that react broadly enough for diagnosis of all
serotypes.

Since respiratory infections with coronaviruses and

rhinoviruses are mild and usually do not require hospitalization, they
are not a major concern in the diagnostic virology laboratory (78).
Laboratory directors must consider the availability, adaptability
and efficiency of a test when selecting a procedure for rapid viral
diagnosis.

Two methodologies were considered for this study:

immunofluorescence.

ELISA and

While commercial IFA reagents were available for

RSV, influenza A and B, parainfluenza virus types 1, 2, and 3, and
adenovirus, the only commercially available ELISA reagents were for RSV
and adenovirus.

Immunofluorescence microscopy had been performed at the

Quain and Ramstad clinic for several years, therefore, no additional
equipment was needed to perform immunofluorescence for detection of
respiratory virus antigens.

Whereas a separate ELISA must be performed

for each specific virus, a pool reagent could be used to screen for
several viruses by immunofluorescence.

For these reasons,
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immunofluorescence was selected as the methodology for this study. '
The purpose of this study was twofold:

first, to determine the

epidemiology of specific respiratory viruses in the Bismarck, North
Dakota area, and second, to determine the efficiency and usefulness of
new monoclonal antibodies and shell vial culture for detection of
respiratory viruses in clinical specimens.

Viral prevalence was

determined by viral culture of NPW and NPS specimens and of throat swabs
previously cultured for GAS.

The ability of shell vial cultures and

immunofluorescence to detect viruses in NPW and NPS specimens was
compared to isolation of the viruses in conventional tube cell culture.
It was our intent to evaluate rapid diagnostic procedures that are
applicable to small hospital laboratories, and provide a rapid
laboratory diagnosis for the management and treatment of viral
respiratory diseases.

MATERIALS AND METHODS

Cell Cultures

Primary monkey kidney (PMK) cells in 16 x 125 mm glass culture
tubes were obtained from Bartels Immunodiagnostics, Incorporated
(Microscan Division, Baxter Healthcare Corporation, West Sacramento,
California).

Cell lines utilized in the study included human laryngeal

epidermoid carcinoma (HEp-2, ATCC CCL 23), human lung carcinoma (A549,
ATCC CCL 185) and human embryonal diploid lung (MRC-5, ATCC CCL 171).
Cell lines were grown to confluency in 75 cm3 culture flasks (Corning
Glass Works, Corning, New York), washed twice in calcium- and magnesiumfree phosphate buffered saline, trypsinized (0.25%) for 10 minutes at
35C and subcultivated at a ratio of 1:8, 1:8, and 1:5, respectively.
The HEp-2 and A549 cell lines were also subcultured to 1 dram shell
vials containing circular 12 mm glass coverslips.

Cells were grown in

Hank's minimal essential medium (H-MEM, Gibco Laboratories, Grand
Island, New York) supplemented with 10% newborn calf serum (NCS, Irvine
Scientific, Santa Ana, California) and the cells were maintained in
Earle's minimal essential medium (E-MEM, Gibco Laboratories, Grand
Island, New York) supplemented with 2% fetal bovine serum (FBS, Gibco
Laboratories, Grand Island, New York).

Culture refeeding medium

consisted of E-MEM supplemented with 3% antibiotic solution containing
penicillin (10,000 Units/ml), streptomycin (10,000 Units/ml) and
amphotericin B (25 ug/ml).

-
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The Study Population and Specimen Procurement

From December, 1987, through June, 1989, respiratory specimens were
submitted to the Microbiology Laboratory at the Quain and Ramstad
Clinic, Bismarck, North Dakota.

Included in the study were

nasopharyngeal swab (NPS), nasopharyngeal wash (NPW) and throat swab
(TS) specimens collected by physicians and nursing personnel.

Specimens

were collected from clinic outpatients or were referred to the
laboratory from neighboring clinics and hospitals.

Collection and Storage of Specimens

Nasopharyngeal Wash (NPW)

The method described by Hall, et al. (75) was used to collect
NPW specimens.

At the patient's bedside, a 1-ounce rubber ear and ulcer

syringe (Davol, Incorporated, Cranston, Rhode Island) was loaded with 3
to 5 ml of sterile phosphate buffered saline (PBS).

With the patient's

head tipped back at about 70 degrees, the bulb was inserted until it
occluded the nostril.

With one complete squeeze and release, the nasal

wash was collected in the bulb.

The bulb contents were then emptied

into a sterile screw-capped tube and transported to the laboratory.
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Nasopharyngeal Swabs (NPS)

Nasopharyngeal swab specimens were collected on Mini-tip
culturettes (Marion Scientific, Kansas city, Missouri) by inserting the
swab 4 to 5 cm into the nostril.

The swab was left in place for

approximately 5 sec, carefully removed, and immediately placed into the
culturette container with modified Stuart's medium for transport to the
laboratory.

Collection of 2 NPS specimens was strongly encouraged in

order to ensure a sufficient number of ciliated epithelial cells for
microscopic examination.

Throat Swabs (TS)

Throat swab specimens were collected on regular culturettes
(Marion Scientific, Kansas City, Missouri) by vigorously swabbing the
tonsillar crypts and pharynx.

Swabs were placed into the culturette

container with Stuart's medium for transport to the laboratory.
All TS, NPW and NPS specimens were stored at 2 to 8C until
processed, usually within 24 hours of receipt.

Detection of Group A Streptococcus (GAS) by Immunofluorescence

Throat swab specimens were inoculated onto tryptic soy agar plates
containing 5% defibrinated sheep red blood cells (DiMed Corporation, St.
Paul, Minnesota), streaked for isolation, and incubated anaerobically
for 16 to 24 hours in a Gas Pak jar (BBL Microbiological Systems, Becton
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Dickinson and Company, Cockeysville, Maryland).

Beta hemolytic colonies

were suspended in a drop of PBS on a glass slide, and the slide was air
dried and fixed with cold ethanol for one minute.

One drop

(approximately 50 ul) of lapine anti-GAS antiserum labeled with
fluorescein isothiocyanate (BBL Microbiological Systems, Becton
Dickinson and Company, Cockeysville, Maryland) was added to each slide.
After 30 minutes incubation at room temperature, the slide was washed in
PBS for 10 minutes, air dried, mounted with buffered glycerol, and read
using an immunofluorescent microscope.

Cocci exhibiting 4+ fluorescence

were interpreted as being positive for GAS.
After being processed for GAS, TS specimens were randomly selected
for viral culture.

Viruses, not screened for by immunofluorescent assay

but isolated in cell culture, were identified by cytopathogenic effect
in cell culture.

Clumping and rounding of MRC-5 and HEp-2 cells with

some syncytial formation was indicative of herpes simplex virus and
generalized cell rounding and destruction, primarily in PMK cells,
signified the presence of an enterovirus.

Immunofluorescent Microscopy

All slides and coverslips were read at a magnification of 200X to
400X with incident light illumination using a Zeiss fluorescent
microscope (Carl Zeiss, Incorporated, Thornwood, New York) equipped with
a tungsten halogen lamp, a 495 nm excitation filter and a 520 nm
emission filter.
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Processing of Throat Swabs, Nasopharyngeal Swabs and Nasopharyngeal'
Washes in Preparation for Cell Culture and Immunofluorescent Staining

Nasopharyngeal washes, NPS in 2 ml PBS, and TS in 2 ml PBS were
vortexed (10 seconds, highest speed setting) to create a primary cell
suspension (PCS).

One ml aliquots of the PCS were stored at -70C.

The

remaining PCS was centrifuged for 5 minutes at 1500 x g in a Beckman
model TJ-6R centrifuge (Beckman Instruments, Incorporated, Palo Alto,
California) to pellet the cells.

The supernatant fluid was stored at 2

to 8C and used to inoculate tube cell culture.

Because they contained

squamous epithelial cells rather than ciliated epithelial cells, the TS
cell pellets were not suitable for direct specimen testing and were
stored at -70C after inoculation of tube cell culture.

The remaining

supernatant fluid was decanted and NPW and NPS cell pellets were
resuspended in the residual PBS.

Direct patient specimens (DPS) were

prepared by placing 1 to 2 drops of the cell suspension onto glass
slides (wettable, acetone resistant; Roboz Surgical Instrument Company,
Incorporated, Washington, D. C.).

The slides were then air dried and

fixed in cold acetone for 10 minutes.

Inoculation and Fixation of Cell Cultures

Conventional Tube Cell Culture

The maintenance medium was decanted from tubes of PMK, HEp-2,
and MRC-5 cells and each cell type was inoculated with 0.2 to 0.5 ml of
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PCS supernatant fluid.

After adding 2 ml of refeeding medium to each

tube, the cultures were incubated at 35C and examined daily for
cytopathogenic effect (CPE).
At 10 days or when CPE was evident, the cell monolayers (CM) were
scraped into the culture medium with a sterile disposable pipette,
vigorously pipetted to suspend the cells, and centrifuged (1500 x g, 5
min).

The supernatant fluid was stored at -70C, and the cell pellet was

resuspended in 2 ml PBS and centrifuged (1500 x g, 5 min).

After

decanting the supernatant fluid, the cell pellet was resuspended in
residual PBS, and the cells were spotted to a glass slide, air dried and
fixed in cold acetone for 10 minutes.

Shell Vial Cultures

Depending upon the test protocol, 0.2 ml of the PCS was
inoculated either into duplicate A549~seeded shell vials or into a
single HEp-2-seeded shell vial.

After centrifugation (1500 x g, 30 min,

25C), the vials were gently agitated, and the excess inoculum was
removed with a disposable pipette.

One ml of refeeding medium was added

to each vial and the cultures were incubated at 35C.
The HEp-2-seeded shell vial cultures were processed 48 hours
postinoculation.

One of the A549~seeded shell vial cultures was

processed at 48 hours postinoculation and the second shell vial was
processed at 5 days postinoculation only if virus antigen was present in
the first vial.

After removal of the maintenance medium, the coverslips
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were washed twice in one ml volumes of PBS (5 minutes each) and fixed in
1 ml of cold acetone for 10 minutes.

Sources of Antibodies and Immunofluorescent Staining Procedures

Indirect Fluorescent Antibody (IFA) Reagents

The IFA reagents (Table 4) were commercially available from
Bartels Immunodiagnostics, Incorporated (Baxter Healthcare Corporation,
Microscan Division, West Sacramento, California) and were supplied as a
panel (Bartels Indirect Fluorescent Antibody Viral Respiratory Panel).
Components of the panel included murine monoclonal antibodies specific
for respiratory syncytial virus (BIFA-RSV), influenza A (BIFA-FA),
influenza B (BIFA-FB), parainfluenza virus types 1, 2, and 3 (BIFA-P1,
BIFA-P2, and BIFA-P3, respectively), and adenovirus (BIFA-Ad), a murine
monoclonal antibody pool and a fluorescein isothiocyanate- (FITC-)
labeled rabbit anti-mouse antibody with Evan's blue counterstain
(conjugate).

The pool reagent contained antibodies specific for RSV,

influenza A and B, parainfluenza virus types 1, 2, and 3, and
adenovirus.

The IFA reagents were used to stain DPS, CM, and A549 shell

vial coverslips.

Indirect Fluorescent Antibody Staining of Direct Patient Specimens
(DPS) and Tube Culture Monolayers (CM)

Specimens were stained first with the pool reagent for virus
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Table 4.

Method

Commercial sources of monoclonal antibodies used in the study.

Specificity of Antibody

Manufacturer

Designation

DFA(l)
Respiratory Syncytial Virus
Respiratory Syncytial Virus
Influenza A Virus
Influenza B Virus
Parainfluenza type 1 Virus
Parainfluenza type 2 Virus
Parainfluenza type 3 Virus
Adenovirus

B( 2)
W( 3)
w
w
w
w
w
w

BDFA-RSV
WDFA-RSV
WDFA-FA
WDFA-FB
WDFA-P1
WDFA-P2
WDFA-P3
WDFA-Ad

Respiratory Syncytial Virus
Influenza A Virus
Influenza B Virus
Parainfluenza type 1 Virus
Parainfluenza type 2 Virus
Parainfluenza type 3 Virus
Adenovirus

B
B
B
B
B
B
B

BIFA-RSV
BIFA-FA
BIFA-FB
BIFA-P1
BIFA-P2
BIFA-P3
BIFA-Ad

IFA(4)

(1)
(2)
(3)
(4)

-

Direct Fluorescent Antibody
Bartels Immunodiagnostics
Whittaker M. A. Bioproducts
Indirect Fluorescent Antibody
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antigen.

If positive, the specimens were stained with the individual

viral reagents for specific identification.

One drop (approximately 50

ul) of pool or virus specific reagent was added to each well.

The

slides were incubated for 30 minutes at 35C in a humidified chamber,
washed in PBS with gentle agitation for 10 minutes and air dried.

One

drop (approximately 50 ul) of conjugate was added to each well and the
slide was incubated for 30 minutes at 35C in a humidified chamber.
After washing with agitation in PBS for 10 minutes, the slide was air
dried and mounted with buffered glycerol.

Indirect Fluorescent Antibody Staining of Shell Vial Coverslips

Coverslips were stained for virus antigen using the pool
reagent.

If positive, the cells on the coverslip of the second shell

vial were harvested, transferred to slides and stained with virusspecific IFA reagents as described above under the section:
staining of DPS.
shell vials.

IFA

All staining and washing procedures were done in the

Two drops (approximately 100 ul) of pool reagent was added

to each shell vial and the recapped vials were incubated at 35C for 30
minutes.

The pool reagent was removed and the coverslips were washed

twice in 1 ml of PBS (5 minutes each).

A bent-tip needle and fine-tip

forceps facilitated removal of the coverslips from the shell vials.
coverslips were air dried (cell side up) and mounted (cell side down)
with phosphate buffered glycerol.

The
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Direct Fluorescent Antibody (DFA) Reagents

The DFA reagents (Table 4) were commercially available from
Bartels Immunodiagnostics, Incorporated (Baxter Healthcare Corporation,
Microscan Division, West Sacramento, California) and from Whittaker (M.
A. Bioproducts, Walkersvilie, Maryland).

All reagents were FITC-

conjugated monoclonal antibodies and included:

Bartels and Whittaker

anti-RSV (BDFA-RSV and WDFA-RSV, respectively), Whittaker anti-influenza
A (WDFA-FA), anti-influenza B (WDFA-FB), anti-parainfluenza types 1, 2,
and 3 (WDFA-P1, WDFA-P2, and WDFA-P3, respectively), and anti-adenovirus
(WDFA-Ad).

The BDFA-RSV reagent was used to stain HEp-2-seeded shell

vial cultures and all DFA reagents were used for staining of DPS.

Direct Fluorescent Antibody Staining of Direct Patient Specimens
(DPS)

One drop (approximately 50 ul) of each DFA reagent was added
to specific wells of the DPS slides.

After incubation at 35C for 30

minutes in a humidified chamber, the slides were washed with gently
agitation in PBS for 10 minutes, air dried and mounted with phosphate
buffered glycerol.
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Direct Fluorescent Antibody Staining of HEp-2-Seeded Shell Vial
Coverslips

Staining and washing of the coverslips were performed directly
in the shell vials.

Two drops (approximately 100 ul) of the BDFA-RSV

reagent was added to each shell vial and the recapped vials were
incubated for 30 minutes at 35C.

The reagent was removed and the

coverslip was washed twice in 1 ml volumes of PBS (5 minutes each).

The

coverslips were removed and mounted as described above under the
section:

IFA staining of shell vial coverslips.

A flow diagram summarizing the protocols used in processing TS, NPS
and NPW specimens is given in Figure 1.

Interpretation of Immunofluorescent Stains

A positive immunofluorescent result (virus antigen present) was
dependent upon observation of specific intracellular fluorescence
patterns:

cytoplasmic for RSV and parainfluenza viruses; nuclear for

influenza viruses; and cytoplasmic and nuclear for adenovirus.

At least

2 fluorescent cells per well were required for a positive result when
reading DPS, CM, and shell vial coverslips.
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Figure 1.

Flow diagram of processing protocols for throat swab,
nasopharyngeal wash and nasopharyngeal swab specimens.
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Nasopharyngeal Wash

Nasopharyngeal Swab
2 ml PBS

Primary Cell Suspension (PCS)
(Store 1 ml at -70C)

Throat Swab
in 2 ml PBS

Centrifuge
(1500 x g, 5 min)

Shell Vial Assay

I

Inoculate 2
Vials A549
Supernatant

Cell Pellet
y
Prepare DPS
for FA, fix in
cold acetone

I

Observe 10 days
or if CPE present

Stain DPS with
individual WDFA,
BIFA pool and
individual BIFA
reagents

Scrape cells,
fix, stain with
BIFA pool reagent

Fix and stain
with BDFA-RSV
reagent

i
Fix, stain with BIFA pool
reagent

V

V
Postive

Stain cells
with
individual
BIFA reagents

1

35C, 48h

Shell Vial fl
Inoculate tube
cell culture

¥
Positive

Inoculate 1
Vial HEp-2

Negative
End

\
After 5 days,
scrape cells
of vial #2, fix
and stain with
individual BIFA
reagents

Negative

1

End

39

Data Analysis

The relative efficiencies of immunofluorescent reagents were
determined by using tube cell culture as the standard.

Sample pairs

which were both culture-positive and immunofluorescence-positive were
considered to be true positives (TP); culture-negative and
immunofluorescence-positive pairs were termed false-positives (FP);
culture-positive and immunofluorescence-negative pairs were termed
false-negative (FN) and specimen pairs that were culture-negative and
immunofluorescence-negative were termed true negative (TN).

Sensitivity

(sens), specificity (spec), and predictive values were calculated as
follows:

sensitivity = (TP/TP + FN) x 100, sensitivity = (TN/TN + FP) x

100, positive predictive value = (TP/TP + FP) x 100, and negative
predictive value = (TN/TN + FN) x 100.

Predictive values as a function

of disease prevalence (prev) were calculated as follows:

positive

predictive value = [(prev)(sens)]/[(prev)(sens) + (1 - prev)(l - spec)]
and predictive value negative = [(1 - prev)(spec)]/[(prev)(1 - sens)] +
[(1 - prev)(spec)].

RESULTS

The Study Population

The period of study was from November, 1987, through June, 1989.
Of a total of 1007 respiratory specimens included in the study, 480
consisted of throat swabs (TS) specimens, 237 were nasopharyngeal
swabs (NPS), and 290 were nasopharyngeal washes (NPW).

The age and

sex distribution of the patients from whom NPW/NPS and TS specimens
were collected is defined in Figures 2 and 3, respectively.
patients, 48% were

male and 52% female.

comprised 4.6% of the population.

Of all

Native American patients

Over half (55.8%) of the

nasopharyngeal specimens were obtained from hospitalized patients.
The majority of the nasopharyngeal specimens were collected from
patients less than or equal to 6 years of age.

The majority of the TS

specimens were obtained from patients between the ages of 1 and 49.

Epidemiology of Group A Streptococcus and Respiratory Viruses in
Bismarck, North Dakota

Isolation of Group A Streptococcus (GAS) and Viruses from Throat
Swabs

Throat swabs which were submitted for identification of GAS
40
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Figure 2.

Age and sex distribution of patients from whom
nasopharyngeal wash and nasopharygeal swab specimens
were obtained. Symbols: Males, (///); Females, (\\\).
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AGE AND SEX DISTRIBUTION
Nasopharyngeal Wash (NPW) and Swab (NPS)

A g e (Years)
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Figure 3.

Age and sex distribution of patients from whom throat
swabs were obtained. Symbols: Males, (///);
Females, (\\\).
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AGE AND SEX DISTRIBUTION
Throat Swab (TS)

A g e (Years)
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were examined also for respiratory viruses (Table 5).

Viruses and/or

GAS were isolated from TS each month during the study period.

Of the

480 specimens examined, 25.4% were positive for GAS and 7.7% were
positive for respiratory virus (Table 5).

In only 4 instances were

GAS present when a virus was isolated from the same swab.

The virus

isolation rate was 8.9% in the GAS-negative specimens and 3.3% in the
GAS-positive specimens.

Seven groups of viruses were found with

influenza A virus having the highest frequency of isolation (Table 6).

Identification of Viruses from Nasopharyngeal Swab and
Nasopharyngeal Wash Specimens

In both respiratory disease years, the identification of
viruses from NPS/NPW specimens was confined to the months of December
through June.

Peak viral identification rates occurred in February of

1988 and in May of 1989 (Table 7).

An overall identification rate of

35.6% and a rate range of 0 to 56% were observed.

The most frequently

identified virus was RSV and the majority of the identifications were
made from NPW specimens (Table 8).

However, only a slight diagnostic

advantage was seen for NPW specimens;

114 identifications were made

from 290 NPW (39.3%) and 74 identifications were made from 237 NPS
(31.2%).

Eight of the viruses identified (5 herpes simplex viruses

and 3 enteroviruses) were not screened for in the immunofluorescent
staining procedure.
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Table 5.

Isolation of group A streptococcus and viruses from throat
swab (TS) specimens.
Group A Streptococcus
Number Isolated
%

Viruses
Number Isolated

Month/Year

Number
Specimens

12/87

15

1

7

2

13

1/88

50

' 15

30

9

18

2/88

20

3

15

1

5

3/88

33

12

36

6

18

4/88

52

13

25

1

2

5/88

52

12

23

2

4

6/88

43

6

14

2

5

7/88

0

8/88

14

4

29

4

29

9/88

0

10/88

40

6

15

3

8

11/88

38

12

32

1

3

12/88

42

15

38

1

2

1/89

2

1

50

1

50

2/89

10

3

30

3

30

3/89

52

14

26

2

4

4/89

17

5

29

0

0

Totals

480

122

25.4

38

%

7.7
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Table 6.

Comparative isolation frequency of viruses in throat swab
specimens.

Virus

Number Isolated

Percent of Total

Influenza A

12

32.4

Enterovirus

7

18.8

Influenza B

5

13.8

Adenovirus

4

10.7

Herpes simplex

3

8.1

Parainfluenza type 1

2

5.4

Parainfluenza type 2

1

2.7

Parainfluenza type 3

1

2.7

Rhinovirus

1

2.7

Respiratory syncytial

1

2.7

37

100.0

Totals
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Table 7.

Identification of viruses from nasopharyngeal specimens. '

Month/Year
11/87

Number of
Specimens
4'

Number of Viruses
Identi fied(a)

Percent

0

0

12/87

17

1

5.9

1/88

37

14

37.8

2/88

50

28

56.0

3/88

49

19

38.8

4/88

20

6

30.0

5/88

2

1

50.0

6/88

No Tests

7/88

No Tests

8/88

No Tests

9/88

No Tests

10/88

1

0

0

11/88

5

0

0

12/88

25

6

24.0

1/89

50

17

34.0

2/89

83

20

24.1

3/89

58

18

31.0

4/89

37

11

29.7

5/89

63

36

51.1

6/89

26

12

46.2

527

189

Totals

(a) - Includes immunofluorescent detection of viruses in direct
patient specimens and isolation of viruses in cell culture.
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Table 8.

Comparative identification frequency of viruses in
nasopharyngeal swab (NPS) and nasopharyngeal wash (NPW)
specimens.

Virus

Identifications
NPW
NPS

Total

Percent

Respiratory
syncytial

34

72

106

55.9

Influenza A

6

18

24

12.8

Influenza B

16

7

23

12.2

Parainfluenza
type 3

6

10

16

8.5

Adenovirus

6

4

10

5.3

Herpes simplex

4

1

5

2.7

Enterovirus

2

1

3

1.5

Parainfluenza
type 1

0

2

2

1.1

74

115

Totals

189

100. 0
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Viral Incidence

In order to optimize the cost effectiveness of
immunofluorescent staining methods, epidemiologic information concerning
the incidence of respiratory viruses in the community must be known.
This allows for the proper selection of reagents for use in routine
staining procedures for respiratory specimens obtained at various times
of the year.

The seasonality and incidence of respiratory viruses in

the Bismarck, North Dakota area are depicted in Figure 4 and Table 9,
respectively.

The seasonality data suggest that respiratory syncytial

virus (RSV), influenza A and influenza B reagents could be excluded from
testing from July through November.

However, the endemic nature of

adenoviruses and parainfluenza viruses necessitated that reagents for
these viruses be included in staining procedures at all times of the
year.

Patients less than 6 years of age and those more than 50 years of

age had the highest viral attack rates; almost half of the patients less
than 12 months of age showed immunofluorescent or culture evidence of
viral infection.

While RSV was the most frequently encountered virus in

the less than 6 year old group, influenza A virus was the most
frequently identified virus in the remaining 4 age groups.

Viral Syndromes

Patients in the study population exhibited a wide variety of
diagnoses and symptoms (Table 10).

By ranking the most frequently

occurring symptoms of patients with disease of known viral etiology,
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Figure 4.

Seasonality of respiratory viruses in Bismarck, North
Dakota from December, 1987 to June, 1989.
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1987

1988

1989
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Table 9.

Incidence
influenza
types 1,
Bismarck,

by age group of respiratory syncytial virus (RSV),
virus types A and B (INF), parainfluenza virus
2, and 3 (PARA), and adenovirus (ADENO) in the
North Dakota area.
VIRUS IDENTIFI CATIONS(b)

Age
Group

No.(a)

< 1

229

81 (35.4)

9 (3.9)

11 (4.8)

6 (2.6)

107 (46.7)

2-6

239

20 (8.4)

21 (8.8)

7 (2.9)

7 (2.9)

55 (23.0)

7-25

229

1 (0.4)

15 (6.6)

2 (0.9)

1 (0.4)

19 (8.3)

26-49

166

0

0

0

5 (3.0)

> 50

144

4 (2.8)

14 (9.7)

2 (1.4)

0

20 (13.9)

106 (10.5)

64 (6.4)

22 (2.2)

Total 1007

RSV

INF

5 (3.0)

PARA

206 (20.5)
(a)
(b)
(c)
(d)
(e)

ADENO

14 (1.4)

Incidence
Per Age
Group (c)

Specific Viral
Incidence (d)

Overall Viral Incidence (e)

Number of specimens in each age group.
Number and percent of specific viruses identified for specific age
groups.
Total number and percent of all viruses identified for specific age
groups.
Total number and percent of specific viruses identified for all age
groups.
Total number and percent of all viruses identified for all age
groups.
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Table 10.

The diagnoses and symptoms, in decreasing order of
frequency,of patients presenting with respiratory illness.

Diagnosis

Symptom

Pneumonia

Cough

Bronchitis

Fever

Upper Respiratory
Infection

Pharyngitis

"Flu"

Rhinorrhea

Bronchiolitis

Respiratory Distress/
Shortness of Breath

Fever of Unknown
Origin

Otitis

Asthma

Malaise

Pharyngitis

Wheezing

Chronic Cough

Vomiting

Pneumonitis

Congestion
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viral syndromes were constructed (Table 11).

Knowledge of these

'

syndromes, in conjunction with known viral incidence in the community,
could be useful to the physician for establishing etiology of disease
and for directing decisions concerning therapy and diagnostic
procedures.

Assessment of Specimen Quality for Immunofluorescent Assay of Direct
Patient Specimens (DPS)

Specimens containing >2 ciliated epithelial cells per 400X field
were judged to be acceptable for immunofluorescent assay (Figure 5).
Overall, 46 (8.7%) of the nasopharyngeal specimens were unacceptable:
34 of 290 NPW specimens and 12 of 237 NPS specimens (Table 12).
a significant effect on specimen quality.

Age had

The rejection rate for

specimens from patients greater than 7 years of age was approximately 5
to 6 times higher than the rate for patients less than 6 years of age.

Interpretation of Immunofluorescent Staining Patterns in Virus-Infected
Ciliated Epithelial Cells

Direct patient specimens were considered positive only when > 2
cells per well had specific intracellular fluorescence.

Typical

immunofluorescence patterns were observed with all BIFA and BDFA-RSV
reagents (Figure 6):

cytoplasmic fluorescence with RSV and

parainfluenza reagents, nuclear fluorescence with the influenza A and B
reagents, and both nuclear and cytoplasmic fluorescence with the
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Table 11.

Syndromes associated with specific viral infections, listed
in decreasing order of frequency.

Virus

Syndrome

Respiratory syncytial

Cough > Fever > Rhinorrhea > Wheezing

Influenza

Fever > Cough > Pharyngitis > Malaise

Parainfluenza type 3

Cough > Wheezing > Fever > Otitis

Adenovirus

Fever > Otitis > Cough > Diarrhea

Herpes simplex

Pharyngitis > Cough > Fever
> Respiratory distress

Enterovirus

Fever > Pharyngitis > Cough > Headache
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Figure 5

A direct patient specimen (DPS) containing > 2 ciliated
epithelial cells (CEC) per 400X field.
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Table 12.

The quality of nasopharyngeal swab (NPS) and nasopharyngeal
wash (NPW) specimens with respect to age.
NPS

Age

Total
Specimens

All

237

< 6 Years
> 7 Years

NPW

Not
Acceptable

%

Total
Specimens

12

5.1

290

34

11.7

116

2

1.7

201

9

4.5

121

10

8.3

89

25

28.1

Not
Acceptable

%

60

Figure 6.

Bartels IFA staining of virus-infected ciliated
epithelial cells (400X). (a, BDFA-RSV; b, BIFA-RSV;
c, BIFA-FA; d, BIFA-P3; and e, BIFA-Ad).
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D

E
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adenovirus reagent.

Immunofluorescent patterns observed with WDFA '

reagents were typical for RSV, parainfluenza, influenza A and adenovirus
(Figure 7).

Influenza B virus-infected cells displayed primarily

cytoplasmic fluorescence that had a tendency to intensify at the brush
border (Figure 7c).

Information concerning the viral epitope against

which the monoclonal antibodies were directed was either unknown or
unavailable from the manufacturers.
Nonspecific background fluorescence was observed in approximately
10% of the specimens which correlated with increased numbers of squamous
epithelial cells and mucus in these specimens (Figure 8).

Efficiency of Immunofluorescence for the Detection' of Respiratory
Viruses in Direct Patient Specimens

The sensitivity, specificity and predictive value of each
immunofluorescent staining method and of each individual reagent for all
subsequent experiments were calculated as previously described.

No

conclusions were made concerning reagents for parainfluenza virus type 1
and 2 because of the low number of isolates.

Comparative Bartels Indirect Fluorescent Antibody (BIFA) and
Culture Data

V
The BIFA procedure resulted in various levels of sensitivity
and specificity (Figure 9 and Table 13).

The sensitivity of the

influenza B, parainfluenza 3 and adenovirus reagents (55.6%, 66.7%, and
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Figure 7.

Whittaker DFA staining of virus-infected ciliated
epithelial cells (400X). (a, WDFA-RSV; b, WDFA-FA
c, WDFA-FB; d, WDFA-P3; and e, WDFA-Ad).
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Figure 8.

Nonspecific staining of a direct patient specimen
(Bartels IFA pool reagent, 400X).
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Figure 9.

Comparative Bartels indirect fluorescent antibody
(BIFA) and culture data.
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BIFA
POSITIVE

POSITIVE

CULTURE

NEGATIVE

NEGATIVE

Respiratory
Syncytial -48
Influenza A -13
Influenza B - 5
Parainfluenza
type 3 - 8
Adenovirus - 3

Influenza B - 4
Parainfluenza
type 3 - 4
Adenovirus - 6

Total -77

Total -14

Respiratory
Syncytial -35
Influenza A - 3
Influenza B -14
Parainfluenza
type 3 - 3
Total -55

Total -274

\
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Table 13.

Efficiency of the Bartels indirect fluorescent antibody
reagents.

Virus

Sensitivity (% )

Specificity I(%)

PPV (%:)*

NPV (%)**

Respi ratory
syncytial

100

87.3

57.8

100

Influenza A

100

98.9

81.3

100

Influenza B

55.6

95.1

26.3

98.6

Parainfluenza
type 3

66.7

98.9

72.7

98.6

Adenovirus

33.3

Overall

84.6

* - Positive predictive value
** - Negative predictive value

100
83.3

100
58.3

97.9
95.1
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50%, respectively) lowered the overall sensitivity of the method to'
84.6%.

The specificities of the individual reagents were excellent,

however, the higher number of false positive RSV and influenza B
reactions resulted in an overall specificity of 83.3%.

The lack of

specificity of the RSV reagent was questionable since evidence suggests
that immunofluorescence is more specific than cell culture for detection
of RSV (63).

The positive and negative predictive values of the test

were 58.3% and 95.1%, respectively.

Table 14 demonstrates the effects

of viral prevalence on the predictive values of the BIFA procedure.

At

low prevalence, these reagents had very high predictive values for a
negative test but very low predictive values for a positive test.

These

data suggest that at low prevalence, a negative result is useful for
deciding on the absence of disease.

As prevalence increases to 50%, the

predictive values for a positive test improve significantly, enhancing
the value of a positive test to confirm the presence of disease.

Comparative Whittaker M. A. Bioproducts Direct Fluorescent Antibody
(WDFA) and Culture Data

High specificity and low sensitivity percentages were obtained
with the WDFA method (Figure 10 and Table 15).

Only the influenza A

reagent was satisfactory while the poorer results with the remaining
reagents lowered the overall sensitivity to 50%.

The positive

predictive value of this procedure was 53.0% and the negative predictive
value was 91.0%.

The effect of varying prevalence rates on the

predictive values of the WDFA reagents is presented in Table 16.

The
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Table 14.

Effect of varying viral prevalence on predictive values of
the Bartels indirect fluorescent antibody reagents.
PREVALENCE (%)

Virus

1

5

10

50

Respiratory
syncytial
PVP*
PVN**

7.4
100

29.3
100

46.7
100

88.7
100

47.9
100

82.7
100

91.0
100

98.9
100

10.3
99.5

37.4
97.6

55.8
95.1

91.9
68.2

23.4
99.7

61.4
98.3

77.1
96.4

96.8
74.8

100
99.3

100
98.7

100
96.6

100
60.0

4.6
99.8

21.1
99.1

36.0
98.0

83.5
84.6

4

Influenza A
PVP
PVN
Influenza B
PVP
PVN
Parainfluenza
type 3
PVP
PVN
Adenovirus
PVP
PVN
Overall
PVP
PVN

* - Predictive value of a positive test, in percent.
** - Predictive value of a negative test, in percent.
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Figure 10.

Comparative Whittaker direct fluorescent antibody
(WDFA) and culture data.

WDFA

POSITIVE
I

POSITIVE

NEGATIVE
4

Respiratory
Syncytial - 8
Influenza A -16
Influenza B - 4
Parainfluenza
type 3 - 2
Adenovirus - 5

Respiratory
Syncytial -13
Influenza A - 1
Influenza B - 5
Parainfluenza
type 3 - 9
Adenovirus - 5

Total -35

Total -33

CULTURE

NEGATIVE

Respiratory
Syncytial -16
Influenza A - 4
Influenza B -11
Total -31

Total
(Respiratory
syncytial
only)
-240
Total -332
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Table 15.

Efficiencies of Whittaker direct fluorescent antibody
reagents.

Virus

Sensitivity (%)

Specificity (%)

PPV (%)*

NPV (%)**

Respi ratory
syncytial

38.1

93.8

33.3

94.9

Influenza A

94.1

98.8

80.0

99.7

Influenza B

44.4

96.8

50.0

98.5

Parainfluenza
type 3

18.2

100

100

97.1

Adenovirus

50.0

100

100

98.7

Overall

50.0

* - Positive predictive value
** - Negative predictive value

91.5

53.0

91.0
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Table 16.

Effect of varying viral prevalence on predictive values of
the Whittaker direct fluorescent antibody reagents.
PREVALENCE (%)

Virus

1

5

10

50

24.4
96.6

40.6
93.2

86.0
60.2

44.5
99.9

80.5
99.7

89.7
99.3

98.7
94.4

12.3
99.4

42.2
97.1

60.7
94.0

93.3
63.5

100
99.1

100
95.9

100
91.7

100
55.0

100
99.5

100
97.4

100
94.7

100
66.7

5.6
99.0

23.6
94.8

39.5
94.3

79.7
64.7

Respiratory
syncytial
PVP*
PVN**

5.8
99.4

;

Influenza A
PVP
PVN
Influenza B
PVP
PVN
Parainfluenza
type 3
PVP
PVN
Adenovirus
PVP
PVN
Overall
PVP
PVN

* - Predictive value of a positive test, in percent.
** - Predictive value of a negative test, in percent.
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100% specificity of the parainfluenza type 3 and adenovirus reagents
account for the 100% positive predictive values.

As with the BIFA

reagents, the WDFA procedure demonstrated the highest negative
predictive values at low prevalence and the highest positive predictive
values at high prevalence.

Comparative Bartels Anti-Respiratory Syncyctial Virus Direct
Fluorescent Antibody (BDFA-RSV) and Culture Data
«

<

The efficiency and predictive values of the BDFA-RSV reagent
compares favorably with the BIFA-RSV reagent (sensitivity 100%,
specificity 89.1%, positive predictive value 63.2% and negative
predictive value 100%) (Figure 11).

These data were not surprising

because the monoclonal antibody used in the BDFA-RSV reagent was the
same antibody used in the BIFA-RSV and BIFA pool reagents.

Efficiency of Shell Vial (SV) Assay for Isolation of Viruses from
Clinical Specimens

Comparative HEp-2 Shell Vial (SV) Assay and Tube Culture Data

Shell vials seeded with HEp-2 cells and stained at 48 hours
with the BDFA-RSV reagent appeared to be superior to HEp-2 tube cell
culture for the isolation of RSV (Figure 12).

Eleven RSV isolations

occurred only in the SV system whereas 1 isolation occurred only in the
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Figure 11.

Comparative Bartels anti-respiratory syncytial virus
direct fluorescent antibody (BDFA-RSV) and culture
data.
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BDFA-RSV

POSITIVE

POSITIVE

NEGATIVE

67

0

39

318

CULTURE
NEGATIVE
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Figure 12.

Comparison of HEp-2-seeded shell vials and
conventional tube cultures for the isolation of
respiratory syncytial virus.
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HEp-2 SHELL VIAL
POSITIVE
POSITIVE

NEGATIVE

15

1

11

37

CULTURE
NEGATIVE
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tube culture.

Isolation of RSV in SV also compared favorable with BDFA

detection of RSV-infected cells in direct patient specimens (Figure 13).

Comparative A549 Shell Vial (SV) Assay and Tube Cell Culture Data

Shell vials seeded with A549 cells and stained at 48 hours
with the BIFA pool reagent failed to isolate 18 viruses that were
isolated by tube cell culture (Figure 14).
isolated only in the A549

£v assay.

Conversely, 1 virus was

Detection of virus-infected cells

in direct patient specimens by BIFA was also superior to isolation of
the viruses in A549 SV (Figure 15).
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Figure 13.

Comparative data for the isolation of respiratory
syncytial virus (RSV) in HEp-2-seeded shell vials
and detection of RSV-infected cells in direct
patient specimens by Bartels anti-RSV direct
fluorescent antibody (BDFA-RSV) reagent.
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HEp-2 SHELL VIAL
POSITIVE
POSITIVE

NEGATIVE

25

5

0

34

BDFA-RSV
NEGATIVE
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Figure 14.

Comparison of A549~seeded shell vials and
conventional tube cell culture for the isolation
of respiratory viruses.
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A549 SHELL VIAL
POSITIVE
POSITIVE

NEGATIVE

2

18

1

88

CULTURE
NEGATIVE
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Figure 15.

Comparative data for the isolation of respiratory
viruses in A549 shell vials and the detection of
virus-infected cells in direct patients specimens by
Bartels indirect fluorescent antibody (BIFA).
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A549 SHELL VIAL
POSITIVE
POSITIVE

NEGATIVE

1

24

2

82

BIFA
NEGATIVE

\

DISCUSSION

Although viral diseases are the most common human infections, it is
paradoxical that most microbiology laboratories do not provide viral
diagnostic services.

This diagnostic deficiency has been exacerbated by

the advent of specific antiviral therapy.

The genuine need for rapid

diagnosis coupled with the development of monoclonal antibodies has
revived immunofluorescence as the a priori method of rapid viral
diagnosis.

Our objectives were to evaluate the efficiency of new

monoclonal antibodies to detect respiratory virus antigens in clinical
specimens and to determine the usefulness of this technique in a
community hospital laboratory.
Immunofluorescent reagents were utilized in this study to detect
viral antigens in direct patient specimens and to stain specimeninoculated cell cultures for virus identification.

This dual diagnostic

role broadened the utility of immunofluorescence by providing a powerful
tool for studying viral epidemiology.

The virologic study of

respiratory specimens collected from hospitalized and outpatient
respiratory specimens provided a good model for virus surveillance.

Our

data demonstrate that throat swabs, submitted for isolation of group A
streptococcus (GAS), could be effectively used for virus isolation.

The

isolation rates for viruses and GAS from throat swab (TS) specimens were
25% and 7.7%, respectively, and compare favorably with a previous study
(87).

Conversely, 67.3% of the TS specimens were negative for both
88
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viruses and GAS.

Since the majority of the patients from whom TS

specimens were obtained consisted of older children and young to middleaged adults, it is possible that Mycoplasma pneumoniae, and
noncultivatable viruses such as coronavirus and Epstein-Barr virus
caused significant morbidity in the culture-negative TS population.

In

studies of acute respiratory syndromes in young adults, one third to one
half of the causes remain unidentified (2).

Four instances of

concomitant virus and GAS infection were identified, including one
isolate each of influenza A, parainfluenza type 1, adenovirus, and
enterovirus.

The concomitant isolation rate of 0.8% is lower than that

reported in similar studies (87,88) and the number of different viruses
isolated in conjunction with GAS suggest that there is no apparent
tendency for one viral infection to predispose more than another to such
an association.

The low concomitant infection rate is surprising since

most of the TS specimens were collected in the winter and spring months
during periods of high respiratory virus and GAS transmission in the
community.

A major complication of viral respiratory infections is

bacterial super infection and the organisms most often associated with
this condition include Streptococcus pneumoniae, Haemophilus influenzae,
and Staphylococcus aureus (89).

That superinfection does not occur

frequently with GAS is suggested in this study not only by the low rate
of concomitant GAS infections but also by a virus isolation rate that
was nearly 3 times higher in the GAS-negative specimens as compared to
the GAS-positive specimens.

These data may conflict with the results of

a study of pharyngitis and tonsillitis among college students (88).
These researchers indicated that virus infection may predispose to
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streptococcal infection (or vice versa) because 27% of the virus
positive patients were concomitantly infected with GAS while the
streptococcal carrier rate in patients without disease was only 8%.
The comparative virus isolation frequencies from TS and
nasopharyngeal (NP) specimens are compatible with the age distribution
of the patients.

Influenza viruses accounted for nearly half of the

virus isolations in the TS group and for 25% of the isolations in the NP
group.

These isolation rates are proportional to the number of patients

of day care and school age in each specimen population and are
consistent with the belief that these children disseminate influenza in
the community and introduce infection into families (2).

The total

number of respiratory syncytial virus (RSV) and parainfluenza virus
(PIV) isolations correlated well with the number of infants and young
children in each specimen population.

Thirty-three percent of the TS

specimens and 61% of the NP specimens were obtained from patients less
than 6 years of age and the respective RSV/PIV isolation rates were
13.5% and 65.5%.
Eight cultures were positive for herpes simplex virus (HSV) which
accounted for 8.3% and 2.7% of the virus isolates for TS and NP
specimens, respectively.

Evans and Dick proposed that HSV may cause

acute tonsillitis or pharyngitis, especially in older children and young
adults (88).

Our data support this finding because 3 of the 8 HSV-

positive patients (ages 1, 16, and 22 years) had pharyngitis without the
presence of oral lesions.

The role of HSV as an etiologic agent of

respiratory disease was obscured in the remaining patients by the
presence of gingival, labial or buccal lesions.
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Pharyngitis was the primary symptom of patients suffering from
enteroviral infection.

Two of the 10 enteroviruses isolated were

identified as coxsackie B4 and echo 2.

Although the etiology was not

proven by neutralization tests performed with the patient's acute and
convalescent sera, the presence of these viruses in the pharynx suggests
that they may have contributed to the clinical picture and support the
contention that pharyngitis is a clinical manifestation of
coxsackievirus and echovirus infections (45).
Adenovirus isolation rates were 10.8% in TS specimens and 5.3% in
NP specimens.

Eleven of the 14 adenovirus-positive patients were

infants less than 2 years of age and the majority of these children had
acute upper respiratory tract symptoms including cough, fever, and
otitis media.

Although these virus isolates were not typed, our data

are consistent with Glezen and Denny who concluded that adenovirus types
1, 2, and 5 have been correlated best with the occurrence of febrile
upper respiratory illnesses in infants under 2 years of age.
A more complete picture of the incidence of respiratory viruses in
the Bismarck, North Dakota area was provided by combining the TS and NP
specimen data.

Infants, young children and adults greater than 50 years

of age had the highest incidence of viral infection;
13.9%, respectively.

46.7%, 23.0%, and

Respiratory syncytial and parainfluenza viruses

were most frequently identified in infants, whereas influenza viruses
and RSV were the most commonly identified agents in young children and
adults over 50 years of age.

The importance of RSV as the major viral

pathogen of infancy and early childhood was supported by a 43.8%
incidence of RSV in children less than 6 years of age and by the finding
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that 30.2% of the RSV isolates were recovered from infants hospitalized
with severe lower respiratory tract disease.

Of 32 infants hospitalized

with RSV infections, 21 (66%) were less than 6 months of age,
demonstrating the unique ability of RSV to cause serious lower
respiratory tract disease even in the presence of maternal antibody (6).
Two of the infants and one elderly patient developed lower respiratory
tract disease serious enough to require treatment with ribavirin.
Although approximately one-third of the hospitalized infants were
premature at birth, no evidence of deficient cellular response could be
found in the medical histories which could account for enhanced
morbidity in this population.
Reinfection with RSV and PIV occurs with appreciable frequency in
older children and adults and probably plays a major role in the spread
of virus to the young infant (2).
support this statement.

Our data show little evidence to

However, RSV and PIV infections in older

children and adults cause mild upper respiratory illnesses which
generally would not result in a physician visitation.
t

I

Because the only
.

.

.

participants included in this study were patients exhibiting respiratory
illness serious enough to seek medical attention, it is probable that
the numbers of RSV and PIV infections in older children and adults were
underestimated.
Although influenza viruses caused significant illness in each age
group, the highest incidence of influenza virus infection was in
patients greater than 50 years of age.

An estimate of influenza

morbidity was made by calculating the percentage of patients
hospitalized in each age group:

infants, 38%; young children, 33%;
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older children and young adults, 33%; adults 26 to 49 years of age, 40%;
and adults greater than 50 years of age, 79%.

These data indicate that

an increased morbidity occurs in elderly patients which is corroborative
of previous reports (3,13).

Welliver and Ogra have speculated that this

increased morbidity in the elderly is due to a waning of immunity
related to diminished proliferative responses and decreased interleukin2 production by cytotoxic T-lymphocytes (6).
Although the vast majority of respiratory infections occurred in
patients less than 6 years of age, adults greater than 50 years of age
had an appreciable number of RSV and PIV infections, reinforcing the
fact that these viruses cause illness throughout life and that a closer
surveillance of our elderly population is warranted.

The overall virus

identification rate of 20.5% emphasizes the scope of viral infections in
the community and explains the heavy burden of morbidity due to viral
respiratory illness.
Epidemics of RSV were observed in both years of the study.

In

1987-88, the epidemic began sharply in January and peaked in February
and the RSV epidemic of 1988-89 had a gradual increase of cases
beginning in February and a peak incidence in May and June.

Although

RSV was predictably epidemic in both years, the peak incidence shifted
from February of the first year to May of the second year.

This finding

is consistent with previous studies that indicated epidemics of RSV
disease occurred yearly but they alternated in their occurrence between
mid-winter and early spring (3,25,27).

Epidemics of influenza A virus

were seen in both respiratory disease years; peak influenza A (H1N1)
activity occurred in February of 1988 and the greatest incidence of
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influenza A (H3N2) was seen in January of 1989.

Although not observed

during 1988, an epidemic of influenza B occurred in 1989 with peak
incidence observed in the months of February and March.

A sharp

demarcation was seen between influenza A and B epidemics; only 1
additional isolation of influenza A was obtained after the first
isolation of influenza B had been made.

The majority of parainfluenza

and adenovirus isolates were detected from December through April of
both respiratory years, with sporadic isolates of both viruses
encountered during the summer and fall.

Adenoviruses were endemic with

at least one infection occurring in 10 out of the 18 months of the
study.
Glezen and Denny observed a type of interference phenomenon that
appeared to influence the occurrence of lower respiratory tract
infections with the major respiratory viruses (25).

In general, when

the peak incidence of one major virus occurred, the other major viruses
were absent.

Our epidemiologic data tend to substantiate their

observation, especially in the second year of the study.

In 1989, peak

epidemic months for influenza A, influenza B, and RSV were observed to
be January, February, and May, respectively, with very little overlap of
isolations.

Parainfluenza type 3 virus was co-circulating during all 5

months but at a very low level.

Although RSV and influenza A virus both

had a peak incidence in February of 1988, parainfluenza virus types 1
and 3 peaked in March and April of 1988, respectively.
A corollary to the interference phenomenon is the fact that the
total illness rate did not vary significantly from year to year
regardless of the number of types of respiratory viruses present.

In
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the first respiratory year of the study, a total of 106 infections were
recognized whereas in the second year, 120 infections were observed.
Even though an epidemic of influenza B did not occur during the first
respiratory year, the total number of infections for each year was
similar.
A necessary prerequisite to successful detection of respiratory
virus antigens in clinical specimens by immunofluorescence was the
collection of specimens with an adequate number of virus-infected
ciliated epithelial cells ('CEC).

Both NPW and NPS specimens were

evaluated for CEC-harvesting efficiency; 5.1% of NPS and 11.7% of NPW
specimens were judged as unsuitable for immunofluorescent assay.

In

patients less than 6 years of age, the overall rejection rate was 3.5%
with the likelihood of rejection nearly 3 times greater for NPW than for
NPS.

The influence of age on harvesting efficiency of CEC was evident

by the 16.7% rejection rate in patients greater than 7 years of age.
The probability of rejecting a NPW in this age group was more than 3
times greater than that of rejecting a NPS.

Respiratory infections in

adults characteristically lack mucus secretion and adults excrete much
less virus antigen than children (80), thus making it difficult to
obtain a good sample for antigen detection.

The difficulty of

successful collection of nasopharyngeal specimens in patients greater
than 7 years of age could be related to amelioration of the infectious
process by an experienced immune system resulting in much less
desquamation and necrosis of the epithelial lining of the nasopharynx.
Previous studies have reported rejection rates of 32% for nasopharyngeal
suctions (81) and 1.8% for pooled NPS and TS (52).

The 8.7% rejection
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rate in this study was acceptable considering that specimens were

'

collected from all age groups.
Approximately 20% of nasopharyngeal specimens in the study were
pooled with TS.

although the amount of nonspecific fluorescence was

generally increased by this action, the recovery of specific viruses in
cell culture was significantly improved.

Of 10 NPS specimens that were

positive for influenza B virus by immunofluorescence but negative by
culture, none were supplemented by a TS specimen, whereas 5 of 6 NPS
specimens positive for infl'uenza B virus by immunofluorescence and
culture were augmented by a TS.
The excellent sensitivity and specificity of the BIFA-RSV and BDFARSV reagents support earlier findings suggesting that immunofluorescence
could replace cell culture as the routine method for diagnosis of RSV
infection (52,84).

The equivalent efficiencies demonstrated by these

reagents corroborate studies that were unable to demonstrate any
significant difference in results between direct and indirect
immunofluorescence methods with respect to RSV detection (52,84).
Although highly specific, the sensitivity of the WDFA-RSV reagent was
inferior to the Bartels reagents.
The impressive performance of the BIFA-FA and WDFA-FA reagents
suggest that either of these reagents could replace cell culture as the
routine method for diagnosis of influenza A infections.

The sensitivity

and specificity of the BIFA-FA reagent (100% and 98.9%, respectively)
and the WDFA-FA reagent (94.1% and 98.8%, respectively) are
significantly better than efficiencies of monoclonal antibodies
previously described (56,72).
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The specificities of the influenza B, parainfluenza type 3 and
adenovirus monoclonal antibodies of both manufacturers were excellent;
however, the sensitivity of each reagent could be improved.

These data

are consistent with the low sensitivities of monoclonal antibodies
reported in previous studies of influenza B (56) and adenovirus (80).
The high specificities of the reagents allow for confident presumptive
diagnoses.
Given the prevalence of disease and the sensitivity and specificity
of the test, one can estimate the probability of disease from a test
result.

The predictive value of a positive test result is an estimate

confirming the presence of disease

while the predictive value of a

negative test result is an estimate that disease is not present (55).
At low prevalence, the BIFA and WDFA procedures demonstrated high
negative predictive values and low positive predictive values indicating
that a negative test result would be useful for ruling out the presence
of disease and that a positive test result would have a low probability
of detecting disease.

At 50% prevalence, the predictive values of a

positive test result for both the BIFA and WDFA procedures are high
enough to be useful in confirming the presence of disease.

One would

have more confidence in ruling out the presence of disease with a
negative BIFA result since the 84.6% negative predictive value for this
procedure was significantly greater than the 64.7% negative predictive
value of the WDFA procedure.
Overall, the BIFA reagents demonstrated a better balance of
sensitivity and specificity than did the WDFA reagents.

Generally, the

WDFA reagents displayed less intense immunofluorescent staining of
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infected cells than did the counterpart BIFA reagents.

The

immunofluorescent staining patterns of the WDFA-RSV and WDFA-FB reagents
were judged to be of a duller and hazier quality as compared to the
BIFA-RSV and BIFA-FB reagents.
A disturbing finding with both the DFA and IFA methodologies was
the apparent high number of false positive results with respect to virus
isolation in cell culture.

Fulton and Middleton have demonstrated that

immunofluorescence had a diagnostic advantage over cell culture
isolation when specimens were taken in the late stages of infection
(81).

Other investigators have presented evidence suggesting that

testing by immunofluorescent assays may result in positive results in
samples taken up to one week after the onset of infection, when
specimens obtained at the same time have become negative for virus by
cell culture (57,90-92).

The clinical histories of the patients whose

specimens demonstrated false positive immunofluorescent results were
reviewed to ascertain the time that the specimens were taken in relation
to the onset of symptoms.

In 14 cases (10 RSV and 4 influenza B

diagnoses, respectively) the patients were symptomatic for 4 to 10 days
prior to specimen collection.

The phenomenon of immunofluorescent

positive and culture negative results could be explained by the
appearance of secretory antibodies which reduce the infectivity of free
virus even though viral antigens may still be present in exfoliated
epithelial cells.
The efficiency of conventional cell culture to isolate all viruses
must be considered in the discussion of false positive immunofluorescent
results.

Since the immunofluorescent reagents were quality controlled
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and specific intracellular patterns of fluorescence were observed,
should one consider the immunofluorescent results falsely positive or
the culture results falsely negative?

Investigators have demonstrated

the inefficiency of cell culture for isolation of RSV (91), influenza
virus (13), parainfluenza viruses (90), and adenovirus (66).

If

reagents have been tried and tested and the reader is absolutely
familiar with the appearance of specific virus fluorescence in clinical
material, then it is possible to make a confident diagnosis by
immunofluorescence alone (77).
Reconsideration of the false positive immunofluorescent results as
true indicators of viral infection results in significant improvement in
the diagnostic power of the BIFA and BDFA-RSV assays.

Examination of

the BIFA and culture comparative data indicates that 91 identifications
could be made by culture alone and that 132 identifications could be
made by immunofluorescence alone.

Similarly, the 106 identifications

made by the BDFA-RSV reagent would be significantly greater than the 67
RSV identifications made by cell culture alone.

Review of the WDFA and

cell culture comparative data indicates no significant difference
between immunofluorescence and cell culture isolation in terms of the
number of positive diagnoses made by each method alone (68 for cell
culture versus 66 for immunofluorescence).

For both the BIFA and BDFA-

RSV reagents, the number of positive diagnoses that would have been made
if immunofluorescence had been the only diagnostic method was
significantly greater than the number that would have been made if only
isolation in cell culture had been used.
Use of both immunofluorescence and cell culture resulted in the
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greatest diagnostic efficiency.

The 146 diagnoses made by the

combination of BIFA and cell culture isolation was significantly greater
than the 132 diagnoses made by immunofluorescence alone or the 91
diagnoses made by culture alone.

Increased diagnostic efficiency was

also observed with tandem use of WDFA reagents and cell culture
isolation.

A total of 99 diagnoses could be made by combining methods,

whereas 31 diagnoses could be made by immunofluorescence alone and 33
diagnoses made by culture alone.
At the present time, rapid diagnosis of viral respiratory
infections is limited to ELISA and immunofluorescent assay.

In our

hands, immunofluorescence was a cost effective and convenient method for
viral diagnosis.

The reagent costs for staining a DPS with the

individual BIFA and WDFA reagents were approximately $1.79 and $1.24,
respectively, which compares favorably with ELISA.

The total time of

testing, including incubations, is 45 minutes for DFA and 90 minutes for
IFA.

Depending upon the manufacturer, ELISA procedures usually can be

performed in 2 to 3 hours.
A positive immunofluorescent result has the potential to reduce or
eliminate the need for routine cell culture which is labor intensive and
requires considerable clinical expertise.

Minnich and Ray calculated

the hands-on time for an individual IFA to be 18.3 minutes and for a
routine cell culture with identification by neutralization to be 82.1
minutes (52).

The difference of 64 minutes for each cell culture

eliminated would result in significant savings in time and money for the
virology laboratory.

It should be noted that decisions concerning the

deletion of cell culture based on rapid detection results must be made
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with caution since viral agents other than those tested for by
immunofluorescence may be present.

Eight viruses that were isolated

from NPW/NPS specimens could not have been detected with the
immunofluorescent reagents used in the study.
The efficiency of shell vial assay for the detection of herpes
simplex virus has been demonstrated in the laboratory at the Quain and
Ramstad Clinic.

Shell vials seeded with MRC-5 cells displayed a 90.9%

sensitivity and a 95.6% specificity when compared to isolation of herpes
simplex virus in tube cell culture.

It was disappointing that the

diagnostic advantage of shell vial assay seen with cytomegalovirus (68)
and herpes simplex virus (69) was not realized for respiratory viruses
in this study.

The HEp-2 shell vial assay more efficiently isolated RSV

than did conventional HEp-2 cell culture, however, immunofluorescent
detection of RSV in DPS was the most efficient method.

Although the

diagnosis of RSV could be made by immunofluorescence alone, the HEp-2
shell vial assay could be a more accurate method of determining the
efficiency of immunofluorescent methods than conventional cell culture,
especially in situations when laboratory personnel are gaining
experience with immunofluorescence.

The A549 shell vial assay was

equivalent to conventional cell culture for the isolation of adenovirus
and RSV but was significantly less sensitive than cell culture for the
isolation of influenza A ana B and parainfluenza type 3 viruses.

These

results suggest that these cultured cells could not be used as a general
purpose host system and corroborate similar findings (93,94).

Perhaps

the use of a different host cell (e.g. primary monkey kidney) would
improve the utility of the shell vial assay for more rapid detection of
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respiratory viruses from clinical specimens.

'

In conclusion, increased use of immunofluorescence for detecting
viral antigens in clinical specimens and in cell cultures would allow
many community hospital laboratories to offer virologic services.

The

BIFA procedure exhibited an acceptable level of sensitivity and
specificity for the accurate and rapid diagnosis of respiratory virus
infection.

Immunofluorescence was judged to be convenient to use, cost

competitive with other rapid diagnostic procedures and readily adaptable
to laboratories equipped with a fluorescence microscope.
Since this study was initiated, there has been an increase in the
number of requests for the laboratory diagnosis of respiratory virus
disease.

Rapid diagnosis of respiratory virus infections by

immunofluorescence has gained general acceptance among the physician
staff at the Quain and Ramstad Clinic as an important diagnostic tool.

SUMMARY

The incidence of respiratory viruses in Bismarck, North Dakota
during consecutive respiratory disease years was determined by
immunofluorescent detection of viral antigens in ciliated epithelial
cells harvested from the respiratory tract and by conventional cell
culture of throat swabs (TS), nasopharyngeal wash (NPW) and
nasopharyngeal swab (NPS) specimens.

These specimens were excellent

tools for studying the epidemiology of respiratory viruses.

Virus

isolation rates of 7.7%, 33.2%, and 39.7% were achieved with TS, NPS and
NPW specimens, respectively.

Epidemics of respiratory syncytial virus

(RSV) and influenza were observed during both years of the study.
Months during which peak RSV activity occurred alternated from February
of the first year to May of the second year.

Parainfluenza virus and

adenovirus activity was endemic in nature throughout the study period.
Children less than 6 years of age and adults greater than 50 years of
age had the highest viral morbidity.

Of the specimens from infants less

than 1 year old, approximately half were virus positive with RSV
comprising 75.6% of the isolates.

Influenza viruses were most commonly

encountered in adolescents and adults.
Nasopharyngeal specimens were evaluated for the ability to harvest
ciliated epithelial cells (CEC) from the upper respiratory tract.
Specimens demonstrating > 2 CEC per 400X field were judged to be
acceptable for immunofluorescent assay.

Overall, 8.7% of all

nasopharyngeal specimens were unsuitable for immunofluorescent assay.
103
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The probability of specimen rejection was type- and age-dependent.

The

rejection rate for NPW specimens was more than twice that for NPS
specimens and the rejection rate for specimens from patients greater
than 7 years of age was approximately 5 times greater than the rejection
rate for specimens from patients less than 6 years of age.
Monoclonal antibodies from 2 commercial sources were used in
immunofluorescent assays to detect virus antigens in respiratory CEC.
When compared to cell culture, immunofluorescent assay was a sensitive
and specific method for rapid diagnosis of respiratory virus infection.
The Bartels indirect fluorescent antibody reagents had acceptable levels
of sensitivity (overall 84.6%, range 33.3 - 100%) and specificity
(overall 83.3%, range 87.3 - 100%).

The Whittaker direct fluorescent

antibody reagents had poor sensitivity (overall 50%, range 18.2 - 94.1%)
and high specificity (overall 91.5%, range 93.8 - 100%).

The highly

efficient Bartels reagents for RSV and influenza A virus could be used
as acceptable alternatives to culture for these viruses.

The

specificity of the influenza B, parainfluenza 3 and adenovirus reagents
would result in a rapid presumptive diagnosis but the reagents are not
sufficiently sensitive to replace culture.
Shell vial assays using HEp-2 and A549 cells offered no diagnostic
advantage over immunofluorescent assay or conventional tube cell culture
for the rapid identification of respiratory viruses.
Immunofluorescent assay using commercial monoclonal antibodies was
a sensitive and specific method for rapid diagnosis of respiratory virus
infections and has the potential to replace expensive and laborious
conventional culture methods.
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